CytoSorbents Corporation — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 14, 2024. This is an annual report, not a standalone Q4 filing. The company develops and sells polymer-based blood-purification devices. Its flagship CytoSorb product is marketed in the EU and other countries; it is not generally approved for commercial sale in the U.S. The filing reports U.S. Emergency Use Authorization for CytoSorb in certain COVID-19 cases, but no COVID-related sales in 2023.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $36.35 million | $34.69 million |
| Product sales | $31.08 million | $29.36 million |
| CytoSorb sales | $31.02 million | $28.57 million |
| Grant income | $5.26 million | $5.33 million |
| Gross profit | $22.39 million | $20.73 million |
| Operating expenses | $53.60 million | $52.25 million |
| Operating loss | $(31.21) million | $(31.52) million |
| Net loss | $(28.51) million | $(32.81) million |
| Net loss per share | $(0.64) | $(0.75) |
| Cash used in operating activities | $(21.66) million | $(28.23) million |
Product gross margin was 72%, up from 70%; management attributed the improvement mainly to the non-recurrence of 2022 manufacturing relocation inefficiencies. The filing’s defined cash burn—cash used in operating and investing activities—was approximately $22.6 million in 2023.
Q4 2023: Revenue was $8.67 million, gross profit was $5.31 million, operating loss was $(9.41) million, and net loss was $(5.83) million, or $(0.12) per share. The filing does not provide a clear quarterly product gross-margin percentage.
Liquidity and debt: At year-end, cash and cash equivalents were $14.13 million, restricted cash was $1.48 million, current assets were $25.70 million, and current liabilities were $14.55 million. Debt principal was $5.0 million, plus an accrued final fee; $2.5 million was classified as current maturities. Monthly principal payments of approximately $208,333 began in January 2024. Management said available cash was expected to fund operations into Q4 2024, but the auditor cited substantial doubt about the company’s ability to continue as a going concern because of recurring losses and cash use. Additional financing is required, with no assurance it will be obtained on acceptable terms.
Material changes versus comparable periods
- Revenue rose 5% from 2022, with CytoSorb sales up 9%. The 2023 increase included an approximately $780,000 benefit from a stronger average euro exchange rate. Revenue remained below 2021’s $43.17 million, when product sales included an estimated $6.3 million related to COVID-19 demand.
- Net loss narrowed by $4.31 million versus 2022. A $1.95 million foreign-currency transaction gain in 2023 compared with a $2.45 million loss in 2022 contributed to the improvement; operating loss remained about $31 million.
- Research and development expense rose 4% to $15.73 million, including pre-production manufacturing and DrugSorb-ATR preparation costs. Legal, financial and consulting expense increased 50% to $4.27 million, including patent-related costs, equity transaction fees and litigation settlement costs.
- Cash and cash equivalents declined from $22.14 million to $14.13 million. Shares outstanding rose from 43.64 million to 54.24 million during 2023, including issuance through the December offering and ATM program.
Outlook, risks and unusual items
- Management’s stated 2024 priorities include completing STAR-T analysis, pursuing U.S. FDA and Health Canada submissions, preparing for potential DrugSorb-ATR commercialization, and returning to sales growth in existing markets. No numerical revenue or earnings guidance is provided.
- STAR-T met its primary safety endpoint but did not meet its primary effectiveness endpoint in the overall study population. The company reported evidence of reduced bleeding complications in the pre-specified isolated CABG subgroup, which represented more than 90% of participants; further analysis and regulatory implications remain to be established. STAR-D was terminated early for business reasons.
- CytoSorb sales are geographically concentrated: Germany accounted for approximately 42% of 2023 net product sales. Reimbursement, hospital adoption, foreign-exchange movements, competition, manufacturing costs and regulatory approvals are material risks. The company reported inflation-related labor, materials and energy cost pressures.
- The EU CE-mark transition period for CytoSorb was extended to December 2028, subject to ongoing requirements. U.S. marketing authorization for DrugSorb-ATR remains uncertain; Breakthrough Device designation is not approval.
- The company raised capital through a December 2023 registered offering, receiving approximately $9.79 million net, and ATM sales, receiving approximately $4.53 million net. These transactions involved substantial share issuance and potential dilution from warrants.
- The company paid $280,000 in November 2023 to settle a litigation matter. A former employee filed a CEPA complaint in March 2024; the company disputes the allegations and intends to defend itself. The filing does not establish the outcome.
- The 10-K describes an immaterial prior-period correction to the 2022 stock-option activity table: options granted had been omitted from that table, and the company revised the disclosure. The filing says the error was not material to prior financial statements.
Most important facts for investors to verify
- Cash runway, monthly debt repayments and the company’s ability to secure financing before its stated Q4 2024 runway.
- Whether CytoSorb sales growth persists without COVID-related demand, and how much growth depends on Germany, distributors and exchange rates.
- Final STAR-T efficacy analyses, the clinical and statistical strength of the CABG subgroup findings, and the regulatory path for DrugSorb-ATR.
- Current reimbursement and market adoption, including the expected impact and cost of the Fresenius marketing program scheduled to launch in 2024.
- Potential dilution from future equity financing, outstanding warrants and equity compensation; also confirm the reported share counts and ATM capacity in subsequent filings.
- Developments in the going-concern risk, debt covenants and the former employee litigation.